A randomized phase 2 study of the antibody-drug conjugate CDX-011
Celldex Therapeutics, Inc. (CLDX) today announced an upcoming data presentation at the American Society of Hematology 54th Annual Meeting and Exposition to be held in Atlanta, GA from December 8 through December 11, 2012. Results from a Phase 1 study of Celldex’s candidate CDX-301 will be presented in a poster session entitled “A Phase 1 Trial of the Hematopoietic Growth Factor CDX-301 (rhuFlt3L) in Healthy Volunteers” on Monday, December 10, 2012 from 6:00 pm to 8:00 pm ET.
This is the SABCS event on Dec 8 for CDX-011
Treatment: Novel Targets and Targeted Agents A randomized phase 2 study of the antibody-drug conjugate CDX-011 in advanced GPNMB-overexpressing breast cancer: The EMERGE study
Yardley DA, Weaver R, Melisko ME, Saleh MN, Arena FP, Forero A, Cigler T, Stopeck A, Citron D, Oliff I, Bechhold R, Loutfi R, Garcia A, Crowley E, Green J, Yellin MJ, Davis TA, Vahdat LT. Florida Cancer Specialists, Tampa, FL; University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN; Georgia Cancer Specialists PC, Sandy Springs, GA; Arena Onc Assoc PC, Lake Success, NY; Bium Inc, Birmingham, AL; Weill Cornell Medical College, New York, NY; Celldex Therapeutics, Inc., Needham, MA; Arizona Cancer Center at the University of Arizona, Tucson, AZ; Cancer Treatment Centers of America/Midwestern Regional Medical Center, Zion, IL; Orchard Healthcare Research Inc., Skokie, IL; Oncology Hematology Care, Cincinnati, OH; Henry Ford Health System, Detroit, MI; USC/Norris Comprehensive Cancer Center, Los Angeles, CA.
This is one of the hottest technologies that oncologists across the World are watching. The target specific delivery of drug to tumor is the treatment of the future. Side effects are minimized and a much higher success profile are the results of CLDX's Antibody Drug Conjugate products. This platform and intellectual value adds hugely to the eventual negotiating price, (whether that be partnership or buyout).